Sermorelin, the shortest synthetic peptide with full GHRH activity, works both as a diagnostic test and treatment for pediatric growth hormone deficiency, though its growth effects may be somewhat less than direct GH replacement.
29 amino acidsSermorelin is the shortest synthetic peptide that retains the full biological activity of human GHRH — making it a landmark in peptide drug design
What the researchers found
Sermorelin, a 29-amino-acid synthetic GHRH analog, serves two clinical roles in children: as a diagnostic test for growth hormone deficiency (via single IV dose of 1 μg/kg) and as a treatment (via daily subcutaneous injection of 30 μg/kg at bedtime). As a diagnostic tool, it produced fewer false positives than other provocative tests. As a treatment, it significantly increased height velocity sustained over 12 months, with limited data suggesting benefits persist through 36 months.
However, sermorelin cannot detect hypothalamic-origin GH deficiency (since it acts at the pituitary level), and its growth-promoting effects appear somewhat less robust than direct growth hormone (somatropin) therapy at equivalent doses.
Why it matters
Sermorelin represents a fundamentally different approach to growth hormone deficiency — instead of replacing the missing hormone directly (like somatropin), it stimulates the body's own pituitary to produce growth hormone naturally. This preserves physiological pulsatile GH release and avoids supraphysiological levels, though at the cost of somewhat less predictable efficacy.
The numbers in context
29 amino acids · Diagnostic: IV 1 μg/kg · Treatment: SC 30 μg/kg/day at bedtime · Growth sustained ≥12 months · Some data to 36 months · Fewer false positives than other GH stimulation tests
How the study worked
Comprehensive literature review of sermorelin's pharmacology, diagnostic utility, and therapeutic efficacy in pediatric growth hormone deficiency, covering clinical trials of both intravenous diagnostic use and subcutaneous therapeutic use.
Who was studied
Prepubertal children with idiopathic growth hormone deficiency
What this study cannot tell us
Published in 1999, so long-term efficacy data (particularly final adult height) was not yet available. Direct head-to-head comparisons with somatropin at the recommended once-daily dose were lacking. Sermorelin cannot diagnose GH deficiency of hypothalamic origin. The therapeutic data was described as 'limited,' with relatively few children studied long-term.
How to read the evidence
Rated moderate because the review covers clinical trial data for both diagnostic and therapeutic uses, but the therapeutic evidence was acknowledged as limited at the time. No single large definitive trial is summarized — the evidence base consists of multiple smaller studies.
When this study was published
Published in 1999, this is a historical reference. Sermorelin's role in pediatric GH deficiency has been largely supplanted by recombinant GH therapy, but the review remains valuable for understanding GH secretagogue pharmacology and for contextualizing modern off-label peptide use.
The bigger picture
Sermorelin was one of the earliest peptide secretagogues to reach clinical use, paving the way for later GH-releasing peptides like CJC-1295, ipamorelin, and tesamorelin. While its clinical use in children has largely been superseded by recombinant GH, it established the concept of stimulating endogenous GH release rather than replacing the hormone — a principle that drives much of today's peptide therapy interest among adults seeking anti-aging and body composition benefits.
Questions still open
- Did long-term sermorelin treatment ultimately improve final adult height, or did its effects plateau?
- How does sermorelin compare to newer GH secretagogues like CJC-1295 or ipamorelin in stimulating endogenous GH release?
- Could combining sermorelin with arginine improve therapeutic outcomes as it does for diagnostic accuracy?
Common questions
What is sermorelin and how does it differ from growth hormone injections?
Is sermorelin still used today?
Read the original research
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 12(2), 139-57
Citation
Prakash, A; Goa, K L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 12(2), 139-57.